Ecolab (ECL)
(Delayed Data from NYSE)
$244.57 USD
-1.16 (-0.47%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $244.55 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$244.57 USD
-1.16 (-0.47%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $244.55 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth B Momentum C VGM
Zacks News
Hawkins (HWKN) Acquires Intercoastal Trading in Maryland
by Zacks Equity Research
Hawkins (HWKN) anticipates that the purchase of Intercostal Trading will be accretive to earnings per share this fiscal year.
Inari's (NARI) Expanding Product Portfolio Offsets Competition
by Zacks Equity Research
Inari's (NARI) VTE products are driving its top line on the back of robust adoption. The company is expanding in additional indications to fuel growth and fight competition.
DexCom (DXCM) Declines on Potential Competition for Stelo
by Zacks Equity Research
DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Three Reasons to Retain BD (BDX) Stock in Your Portfolio Now
by Zacks Equity Research
BD's (BDX) robust product portfolio raises optimism about the stock.
Patterson Companies' (PDCO) New Launch to Boost Patient Service
by Zacks Equity Research
Patterson Companies' (PDCO) Patterson CarePay+ is likely to improve overall patient care and streamline practice operations.
ClearPoint's (CLPT) New Products to Boost Neurosurgical Segment
by Zacks Equity Research
ClearPoint (CLPT) announces the full market release of the SmartFrame OR platform, intended for performing DBS, and Prism Neuro Laser Therapy System for providing thermal therapy.
U.S. Steel (X), Nippon Steel Clear Non-US Regulatory Hurdles
by Zacks Equity Research
U.S. Steel (X) and Nippon Steel receive all necessary non-U.S. regulatory approvals for their transaction, which is expected to close in second-half 2024.
ArcelorMittal (MT) Buys Italpannelli's Italy & Spain-Based Units
by Zacks Equity Research
ArcelorMittal's (MT) construction arm gains significant strategic value from the acquisition of Italpannelli SRL and Italpannelli Iberica.
New Gold (NGD) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
New Gold (NGD) gains from ongoing exploration efforts and an upbeat outlook.
Ingevity (NGVT) Down 12.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Ingevity (NGVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Surmodics (SRDX) Enters Deal to be Acquired by GTCR for $627M
by Zacks Equity Research
Surmodics (SRDX) enters a definitive agreement to be acquired by renowned private equity company GTCR at an estimated total equity valuation of $627 million.
LyondellBasell (LYB) Expands Saudi Presence With NATPET Stake
by Zacks Equity Research
LyondellBasell (LYB) acquires a 35% stake in NATPET from Alujain, boosting its PP business and Saudi presence with plans for a new propylene facility.
BHP Group (BHP) Drops Acquisition Plan for Anglo American
by Zacks Equity Research
BHP Group (BHP) resolves not to make any further offer for Anglo American, thus walking away from a deal that would have been the biggest mining deal in a decade.
DaVita (DVA) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about DaVita's (DVA) strength in kidney care.
What Makes Axalta Coating (AXTA) a Solid Choice Right Now
by Zacks Equity Research
Axalta Coating (AXTA) looks promising at the moment based on its robust Q1 results and the acquisition of The CoverFlexx Group.
Air Products (APD) to Build New Refueling Stations in California
by Zacks Equity Research
Air Products' (APD) new stations will offer improved fuelling technology capabilities, including increased capacity, numerous fueling dispensers and servicing for heavy- and light-duty vehicles.
Here's Why You Should Add Lantheus (LNTH) to Your Portfolio Now
by Zacks Equity Research
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
Stryker (SYK) to Launch Gamma4 Hip Fracture System in Europe
by Zacks Equity Research
Stryker (SYK) announces plan to launch its Gamma4 Hip Fracture Nailing System in Europe. It completes initial surgeries successfully.
Why Is Ecolab (ECL) Up 0.5% Since Last Earnings Report?
by Zacks Equity Research
Ecolab (ECL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reasons Why You Should Retain Avantor (AVTR) Stock for Now
by Zacks Equity Research
Avantor's (AVTR) strong product portfolio raises optimism about the stock.
FMC Receives Registration for Two Herbicides in Brazil
by Zacks Equity Research
FMC believes that Azugro and Ezanya herbicides will help growers control weeds that are resistant to other herbicides, resulting in a healthier harvest.
Stryker (SYK) Issues Safety Notice for Its Total Knee System
by Zacks Equity Research
Stryker (SYK) issues urgent field safety notice for the Mako Total Knee systems, the application software of which generated software error codes. The company also shares risk mitigation steps.
Reasons to Retain PacBio (PACB) Stock in Your Portfolio
by Zacks Equity Research
PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.
Universal Stainless (USAP) Shares Scale 52-Week High: Here's Why
by Zacks Equity Research
Universal Stainless' (USAP) rally reflects a robust first-quarter performance on the back of record aerospace sales.